Advertisement

Document › Details
Memo Therapeutics AG. (2/1/19). "Press Release: Memo Therapeutics Announces the Development of a Droplet Sorter Enabling Functional Antibody Screening in a High-Throughput Format".
This novel microfluidic droplet sorter will be deployed downstream of the MemoMAB antibody repertoire biobanking platform to enable functional screening in high througput format with a series of functional assays such as:
Cell-binding
Virus-neutralization
Identification of agonistic/antagonistic antibodies
ADCC assays
“This is a major step in the technology development at Memo since we are now able to directly screen antibody repertoire libraries from rare patients or immunized animals for antibodies with the desired functional activity in a single day. “ says Dr. Christoph Esslinger, CSO.
Dr. Karsten Fischer, CEO, comments: “Having such a tool at hand will enable us to pick the optimal antibody development candidates out of diverse repertoires for our own pipeline and attract high-profile partnerships with pharmaceutical companies.”
On the coprorate side, Memo has followed the planned trajectory and has moved its premises to State-of-the-art laboratories at Schlieren and launched a new corporate design including a new web site that can be visited at: http://www.memo-therapeutics.com
About Memo
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology.
Record changed: 2019-02-15 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Memo Therapeutics AG
- [1] Memo Therapeutics AG. (11/5/20). "Press Release: Memo Therapeutics AG Raises CHF 14 Million in a Series B Financing Round". Schlieren....
- [2] Memo Therapeutics AG. (6/11/18). "Press Release: Memo Therapeutics AG Announced that Dr. Karsten Fischer Was Appointed as Chief Executive Officer of the Company Effective June 01, 2018". Basel....
- [3] Memo Therapeutics AG. (5/9/18). "Press Release: Memo Therapeutics AG Closes Series A2 Financing Round of CHF 5 Million to Advance Its Antibody Discovery Programs into Preclinical and Clinical Development". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
» top